Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenelzine
Drug ID BADD_D01750
Description Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder.[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Indications and Usage Phenelzine is indicated for the treatment of nonendogenous, neurotic or atypical depression for patients that do not tolerate other forms of therapy.[L1356] Atypical depression has a high prevalence rate, starts in early life, tends to last longer, is more likely to occur in people with bipolar disorder, has a high comorbidity with anxiety disorder and carries more risk of suicidal behavior. It is important to specify the atypical feature to predict the clinical course of depression and hence generate the best treatment and service. The featuring symptoms of the atypical feature include mood reactivity, two or more of this symptoms: 1) increased appetite, 2) increased sleep, 3) leaden paralysis and 4) interpersonal rejection sensitivity and should not have melancholic or catatonic features of depression.[A31917] Neurotic depression is a depression of an emotionally unstable person. It is a secondary condition to major personality disorder, neuroses and drug use disorders. Likewise, a primary depression with a family history of depression spectrum disease would fit in this category.[A31922] A nonendogenous depression is characterized by a disturbance in mood and general outlook. The physical symptoms tend to be less severe and it often occurs in response to stressful life events that keep occurring over a large period of time generating a continuous stress in the daily living.[A31924]
Marketing Status approved
ATC Code N06AF03
DrugBank ID DB00780
KEGG ID D08349
MeSH ID D010624
PubChem ID 3675
TTD Drug ID D0P9AC
NDC Product Code Not Available
UNII O408N561GF
Synonyms Phenelzine | beta-Phenylethylhydrazine | beta Phenylethylhydrazine | Fenelzin | Phenethylhydrazine | 2-Phenethylhydrazine | 2 Phenethylhydrazine | Phenelzine Sulfate | Sulfate, Phenelzine | Nardelzine | Nardil
Chemical Information
Molecular Formula C8H12N2
CAS Registry Number 51-71-8
SMILES C1=CC=C(C=C1)CCNN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute psychosis19.03.01.0010.000094%Not Available
Agitation19.06.02.001; 17.02.05.0120.000062%
Akathisia19.06.02.006; 17.01.02.002--
Anorgasmia19.08.01.001--
Anxiety19.06.02.0020.000094%
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Blood creatine phosphokinase increased13.04.01.001--
Body temperature increased13.15.01.001--Not Available
Cardiac failure02.05.01.0010.000062%
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003--Not Available
Coma17.02.09.001--Not Available
Confusional state19.13.01.001; 17.02.03.0050.000062%
Constipation07.02.02.001--
Delirium19.13.02.0010.000062%
Depression19.15.01.0010.000125%
Depression suicidal19.15.01.0040.000062%Not Available
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.0010.000425%Not Available
Drug ineffective08.06.01.0060.000911%Not Available
Drug interaction08.06.03.0010.000125%Not Available
Dry mouth07.06.01.002--
Dyspepsia07.01.02.001--
Euphoric mood19.04.02.006--
Fatigue08.01.01.0020.000062%
Feeling abnormal08.01.09.014--Not Available
Feeling jittery08.01.09.016--Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages